Sondeo del sistema cannabinoide en personas con antecedentes familiares de psicosis
The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase temprana 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Connecticut
-
West Haven, Connecticut, Estados Unidos, 06516
- VA Connecticut Healthcare System
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria FHP:
- Exposure to cannabis at least once in their lifetime
- Medically and psychiatrically healthy based on screening
- Having one relative with a confirmed psychotic disorder
Exclusion Criteria FHP:
- Current or lifetime major DSM-IV Axis I disorder
- Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
- Major or unstable medical illness that might impact safety of the subject in the study
- Cannabis naive
- IQ less than 85
- Less than a high school diploma or its educational equivalent
- Pregnancy or lactation
- Major current or recent (<6 weeks) psychosocial stressors.
Inclusion Criteria FHN :
- Exposure to cannabis at least once in their lifetime
- Medically and psychiatrically healthy based on screening
Exclusion Criteria FHN:
- Having a family member with psychosis
- Current or lifetime major DSM-IV Axis I disorder
- Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
- Major or unstable medical illness that might impact safety of the subject in the study
- Cannabis naive
- IQ less than 85
- Less than a high school diploma or its educational equivalent
- Pregnancy or lactation
- Major current or recent (<6 weeks) psychosocial stressors.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Otro: No Family History of Psychosis (FHN)
Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions. |
placebo Subjects will receive 0.010mg/kg.
Otros nombres:
Subjects will receive 0.018 mg/kg over 20 minutes.
Otros nombres:
|
|
Experimental: Family History of Psychosis (FHP)
Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions. |
placebo Subjects will receive 0.010mg/kg.
Otros nombres:
Subjects will receive 0.018 mg/kg over 20 minutes.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Periodo de tiempo: -30 min from administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
-30 min from administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Periodo de tiempo: +80 min from administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+80 min from administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Periodo de tiempo: +150 min of administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+150 min of administration of THC
|
|
Positive and Negative Symptom Scale for Schizophrenia (PANSS)
Periodo de tiempo: +240 min of administration of THC
|
Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. |
+240 min of administration of THC
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinician Administered Dissociative Symptoms Scale (CADSS)
Periodo de tiempo: -30 min, +15 min, +80 min, +150 min, +240 min
|
Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment. |
-30 min, +15 min, +80 min, +150 min, +240 min
|
|
Visual Analog Scale (VAS)
Periodo de tiempo: -30 min, +15 min, +80 min, +150 min, +240 min
|
Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high", "anxious", "calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects. |
-30 min, +15 min, +80 min, +150 min, +240 min
|
|
Hopkins Verbal Learning Test (HVLT)
Periodo de tiempo: +50 min
|
The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects. |
+50 min
|
|
Psychotomimetic States Inventory (PSI)
Periodo de tiempo: -30 min, +240 min
|
The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC. |
-30 min, +240 min
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Mohini Ranganathan, MD, Yale University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 1310012948
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .